These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29570919)

  • 21. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-organ failure with fatal outcome: a case report.
    Miszewska-Szyszkowska D; Mikołajczyk N; Komuda-Leszek E; Wieczorek-Godlewska R; Świder R; Dęborska-Materkowska D; Szmidt J; Durlik M
    Ann Transplant; 2015 Mar; 20():169-74. PubMed ID: 25813912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CMV management in a post-kidney-transplant child.
    Elshihabi I
    Transplant Proc; 1994 Feb; 26(1):131. PubMed ID: 8108907
    [No Abstract]   [Full Text] [Related]  

  • 24. Infection-Related Focal Segmental Glomerulosclerosis in Children.
    Dettmar AK; Oh J
    Biomed Res Int; 2016; 2016():7351964. PubMed ID: 27294131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrotic Syndrome Post-Kidney Transplant.
    Hennigar RA; Klein CL
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1347-1350. PubMed ID: 28596417
    [No Abstract]   [Full Text] [Related]  

  • 26. Human cytomegalovirus and kidney transplantation: a clinician's update.
    De Keyzer K; Van Laecke S; Peeters P; Vanholder R
    Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
    Sohrabi M; Behzadian F; Hosseini SM; Lashini H
    Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prospective study of collapsing focal segmental glomerulosclerosis.
    Raja R; Nada R; Yadav AK; Kumar A; Goyal A; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
    Ren Fail; 2016 Jul; 38(6):894-8. PubMed ID: 27266801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focal Segmental Glomerulosclerosis (FSGS) Progressing to Collapsing Glomerulopathy in Renal Transplant Recipients With and Without COVID-19 Infection.
    Thorburn CA; Samarapungavan D; Kanaan HD; Cohn S; Jabbar KJ; Li W; Bedi D; Suliman ST; Patel PJ; Putchakayala K; Singh A; Zhang PL
    Transplant Proc; 2022; 54(6):1465-1470. PubMed ID: 35341587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Focal and segmental glomerulosclerosis in renal allograft recipients: a clinico-pathologic study of 37 cases.
    Gupta R; Sharma A; Mahanta PJ; Agarwal SK; Dinda AK
    Saudi J Kidney Dis Transpl; 2013 Jan; 24(1):8-14. PubMed ID: 23354185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
    Martin M; Goyette N; Ives J; Boivin G
    J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collapsing glomerulopathy.
    Schwimmer JA; Markowitz GS; Valeri A; Appel GB
    Semin Nephrol; 2003 Mar; 23(2):209-18. PubMed ID: 12704581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M; Remport A; Hídvégi M; Péter A; Kóbori L; Telkes G; Fazakas J; Gerlei Z; Sárváry E; Sulyok B; Járay J
    Transpl Infect Dis; 2005 Jun; 7(2):63-7. PubMed ID: 16150092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
    Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of human cytomegalovirus UL97 D605E mutation in transplant recipients in China.
    Zhou L; Fan J; Zheng SS; Ma WH
    Transplant Proc; 2006 Nov; 38(9):2926-8. PubMed ID: 17112867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy.
    Gilbert C; LeBlanc MH; Boivin G
    Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient.
    Puliyanda DP; Silverman NS; Lehman D; Vo A; Bunnapradist S; Radha RK; Toyoda M; Jordan SC
    Transpl Infect Dis; 2005 Jun; 7(2):71-4. PubMed ID: 16150094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate.
    Pascual J; Torrealba J; Myers J; Tome S; Samaniego M; Musat A; Djamali A
    Osteoporos Int; 2007 Oct; 18(10):1435-8. PubMed ID: 17404782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.